Technologies available for partnering or licensing
-
Circulating tumour DNA for monitoring disease burden and genomic changes in cancer
-
SwitchCAR; converts TGFβ signalling into immunostimulation in CAR-T cell therapy
-
Novel inhibitors of perforin
-
Innovative foldamers targeting CCK-2 as theranostic agents in cancer
-
IRF9 as a novel prognostic biomarker in breast cancer
-
Cas13b for Precision Silencing of Transcripts
-
CRISPR engineering methods for armoured CAR-T cell therapies
Tangible materials available for licensing
-
Fully human monoclonal antibody against Ryk
-
Novel leukaemia stem cell line
We have a broad portfolio of early-stage research opportunities available for partnering and/or licensing.